Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06352619




Registration number
NCT06352619
Ethics application status
Date submitted
2/04/2024
Date registered
8/04/2024

Titles & IDs
Public title
Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial
Scientific title
Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL_ENCHANTED3/MT)
Secondary ID [1] 0 0
ACT-GLOBAL_AIS_03
Universal Trial Number (UTN)
Trial acronym
ENCHANTED3/MT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ischemic Stroke, Acute 0 0
Condition category
Condition code
Stroke 0 0 0 0
Haemorrhagic
Stroke 0 0 0 0
Ischaemic
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Conservative SBP Control
Other interventions - Moderate SBP Control
Other interventions - Intensive SBP Control

Experimental: Conservative SBP Control -

Experimental: Moderate SBP Control -

Experimental: Intensive SBP Control -


Other interventions: Conservative SBP Control
No or minimal treatment; if there is a need to treat a patient with a very-high (\>180 mmHg) baseline SBP, then the SBP reduction is 5-10mmHg or a target is 175-180 mmHg

Other interventions: Moderate SBP Control
If the patient has a very high (\>180 mmHg) or moderate high (160-180 mmHg) baseline SBP, SBP reduction is 10-20mmHg or a target of160±5 mmHg, which is higher; patients with low-high (150-160 mmHg) baseline SBP will not be treated

Other interventions: Intensive SBP Control
SBP reduction by 30-50mmHg or a target of 140±5 mmHg, which is higher
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
modified Rankin scale
Timepoint [1] 0 0
90 days
Secondary outcome [1] 0 0
Excellent functional neurological outcome
Timepoint [1] 0 0
90 days
Secondary outcome [2] 0 0
Independent functional neurological outcome
Timepoint [2] 0 0
90 days
Secondary outcome [3] 0 0
Health Related Quality of Life
Timepoint [3] 0 0
90 days
Secondary outcome [4] 0 0
Mortality
Timepoint [4] 0 0
90 days
Secondary outcome [5] 0 0
Ordinal shift of 7 levels of modified Rankin scale
Timepoint [5] 0 0
90 days
Secondary outcome [6] 0 0
National Institute of Health Stroke Scale (NIHSS) score
Timepoint [6] 0 0
24-48 hours
Secondary outcome [7] 0 0
Any intracranial haemorrhage (ICH)
Timepoint [7] 0 0
2 days
Secondary outcome [8] 0 0
Symptomatic intracerebral haemorrhage (sICH)
Timepoint [8] 0 0
2 days
Secondary outcome [9] 0 0
Serious Adverse Event (SAE)
Timepoint [9] 0 0
4 days

Eligibility
Key inclusion criteria
1. Age =18 years;
2. Use of endovascular therapy (EVT) within 24 hours of symptom onset or last known well according to local guidelines;
3. Sustained high systolic blood pressure =150 mmHg (2 readings <10 mins apart) within 3 hours after completion of EVT.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1.Any definite contraindications to BP lowering treatment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/10/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/05/2026
Actual
Sample size
Target
2000
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
The George Institute for Global Health - Sydney
Recruitment postcode(s) [1] 0 0
2000 - Sydney
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Alberta

Funding & Sponsors
Primary sponsor type
Other
Name
The George Institute
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
University of Calgary
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Changhai Hospital
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Craig Anderson, PhD
Address 0 0
The George Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Xiaoying Chen, PhD
Address 0 0
Country 0 0
Phone 0 0
+61 2 8052 4549
Fax 0 0
Email 0 0
xchen@georgeinstitute.org.au
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
After this domain is completed, the archived de-identified limited dataset of randomized participants will be transmitted to and stored in the ACT-GLOBAL Data Repository, for use by researchers. Data can be shared after publication of the main results.

Supporting document/s available: Study protocol
When will data be available (start and end dates)?
Data can be shared after publication of the main results.
Available to whom?
Data can be shared after publication of the main results, based on approval of a submitted protocol to the Publication Committee. Data can be shared to bona fide researchers with experience in medical research, and with no conflict of interest that may potentially influence their interpretation of any analyses, and employed by a recognised academic institute, health service organisation, commercial research organisation of from the pharmaceutical industry. The data sharing will be only for analyses within the constraints of the consent under which the data were originally gathered consent.

Data sharing with industry will be according to relevant contracts with appropriate approvals from all stake holders.
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06352619